FORCE

A Strategic Alliance of AJMC

January 27, 2020
CMS said it is expanding coverage of next generation sequencing (NGS) for use as a diagnostic for patients with germline breast and ovarian cancer, paving the way for Medicare beneficiaries to receive more personalized medicine. However, an advocate said the wording of CMS' decision could actually limit testing access for some women with breast or ovarian cancer.
August 15, 2019
Authors from Facing Our Risk of Cancer Empowered (FORCE), a nonprofit organization focused on hereditary cancer, discuss the importance of genetic testing, guidelines, and coverage considerations.
July 23, 2019
Many people associate the BRCA mutations with breast and ovarian cancer and mistakenly think they, and other genes that contribute to cancer, don’t affect men, said Sue Friedman, DVM, executive director of FORCE: Facing Our Risk of Cancer Empowered.
June 13, 2019
Genetic testing and understanding family history of cancer is important because more and more targeted therapies are coming out that are designed to work with specific mutations or inherited forms of mutations, said Sue Friedman, DVM, executive director of FORCE: Facing Our Risk of Cancer Empowered.
August 01, 2018
Facing Our Risk of Cancer Empowered has announced the receipients of its 2018 Empowerment Awards.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.